The short answer: Most people notice less hunger within the first few weeks, but the scale moves slowly at first because the starting dose is only a first step. In the largest Zepbound (tirzepatide) trial, average weight loss reached roughly 15% to 22% of body weight at 72 weeks, depending on the dose, and it
On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. This makes Zepbound the only drug in history to be approved specifically for OSA — a condition that affects an estimated 30 million Americans and has, until now, been
